Excerpt from Posterior Polymorphous Corneal DystrophySynonyms, Key Words, and Related Terms: PPMD, posterior polymorphous dystrophy, posterior endothelial dystrophy, hereditary deep dystrophy, PPCD Please click here to view the full topic text: Posterior Polymorphous Corneal DystrophyBackgroundFirst described by Koeppe in 1892, posterior polymorphous corneal dystrophy (PPMD) is a dominantly inherited condition characterized by particular alterations of the Descemet membrane and the corneal endothelium. Typically, the corneal changes are either slowly progressive or nonprogressive. In severe cases, corneal decompensation and edema can occur. Although PPMD is most often a bilateral condition, marked asymmetry in the degree of involvement may be seen. Most persons with PPMD are asymptomatic. PathophysiologyThree main abnormalities are described: vesicular changes, endothelial band lesions, and irregular opacities of the posterior corneal surface. The corneal endothelium undergoes a transformation and demonstrates many epithelial characteristics on examination with electron microscopy and immunohistochemical analysis. Often, the endothelium is found to be multilayered. FrequencyUnited StatesThe frequency of PPMD is not well documented. Although it is considered to be uncommon, PPMD may be recognized and diagnosed more often in recent years than in the past. Mortality/MorbidityThe effect of PPMD on patients is highly variable, with a broad clinical spectrum of findings, ranging from nonprogressive asymptomatic disease to progressive or advanced debilitating corneal disease with corneal decompensation and glaucoma. RaceNo racial predilection exists. SexNo sexual predilection exists. AgeAlthough PPMD is an inherited corneal dystrophy, the age at diagnosis is highly variable because of the broad spectrum of disease severity. Findings may be present at birth. Most patients are first identified at age 30-50 years; however, this is likely only indicative of a more common age for ocular examinations.
Please click here to view the full topic text: Posterior Polymorphous Corneal Dystrophy |
| About Us | Privacy | Code of Ethics | Terms of Use | Contact Us | Advertising | Institutional Subscribers |
|
|
|||
|
| Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER |